Key points are not available for this paper at this time.
Transparency and sharing of information from clinicaltrials have developed swiftly during the past 2 years. That pace has continued in 2014 with the Euro-pean Medicines Agencys decision to share some of the information that it receives as part of the approval pro-cess for a new medicine (1), the implementation of prin-ciples on data-sharing by major pharmaceutical com-panies (2), and the release of the Institute of Medicines consensus study (3). Much of the discussion in medical journals has focused on the pharmaceutical industry sharing data with investigators funded by academia or the government (4). As persons with careers in aca-demic medicine, government, and medical publishing, as well as the pharmaceutical industry, we offer our per-spective on the benefits and risks of data-sharing and the value of uniform data-sharing principles.
Rosenblatt et al. (2015) studied this question.